Intravenous tenecteplase in acute ischemic stroke: an updated review

被引：20

作者：

Behrouz, Reza ^{[1
]}

机构：

[1] Ohio State Univ, Dept Neurol, Div Cerebrovasc Dis & Neurol Crit Care, Coll Med, Columbus, OH 43215 USA

来源：

JOURNAL OF NEUROLOGY | 2014年 / 261卷 / 06期

关键词：

Stroke; Cerebrovascular disease; Tenecteplase; Alteplase; Tissue plasminogen activator; Thrombolytics; Thrombolysis; Pharmacology; TISSUE-PLASMINOGEN ACTIVATOR; RANDOMIZED-TRIAL; ALTEPLASE; DESMOTEPLASE; INFARCTION; ANCROD; WINDOW; DIAS;

D O I：

10.1007/s00415-013-7102-0

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Tenecteplase in a genetically engineered variant of alteplase. Although the two have the same mechanism of action, tenecteplase has properties that makes it a seemingly more advantageous thrombolytic. Because of its rapid single-bolus administration, its use is favored over alteplase in the treatment of acute myocardial infarction. Over the past few years, several clinical studies have been conducted to assess the safety, feasibility, and efficacy of tenecteplase in ischemic stroke. In spite of the mixed results of these studies, experimentation with tenecteplase continues in from of clinical trials. In this article, the utility of tenecteplase in ischemic stroke will be discussed.

引用

页码：1069 / 1072

页数：4

共 18 条

[1] Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaernic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial [J].

Bluhmki, Erich ;

Chamorro, Angel ;

Davalos, Antoni ;

Machnig, Thomas ;

Sauce, Christophe ;

Wahlgren, Nils ;

Wardlaw, Joanna ;

Hacke, Werner .

LANCET NEUROLOGY, 2009, 8 (12) :1095-1102

[2] Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model [J].

Chapman, DF ;

Lyden, P ;

Lapchak, PA ;

Nunez, S ;

Thibodeaux, H ;

Zivin, J .

STROKE, 2001, 32 (03) :748-752

[3]

ClinicalTrials.gov, TNK TPA EV MIN ISCH

[4]

ClinicalTrials.gov, ALT TEN TRIAL EV STR

[5] Tenecteplase: A review [J].

Davydov, L ;

Cheng, JWM .

CLINICAL THERAPEUTICS, 2001, 23 (07) :982-997

[6]

González RG, 2012, NEW ENGL J MED, V367, P275, DOI 10.1056/NEJMc1205829

[7] The Desmoteplase In Acute Ischemic Stroke Trial (DIAS) - A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase [J].

Hacke, W ;

Albers, G ;

Al-Rawi, Y ;

Bogousslavsky, J ;

Davalos, A ;

Eliasziw, M ;

Fischer, M ;

Furlan, A ;

Kaste, M ;

Lees, KR ;

Soehngen, M ;

Warach, S .

STROKE, 2005, 36 (01) :66-73

[8] Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke Results of a Prematurely Terminated Randomized Clinical Trial [J].

Haley, E. Clarke, Jr. ;

Thompson, John L. P. ;

Grotta, James C. ;

Lyden, Patrick D. ;

Hemmen, Thomas G. ;

Brown, Devin L. ;

Fanale, Christopher ;

Libman, Richard ;

Kwiatkowski, Thomas G. ;

Llinas, Rafael H. ;

Levine, Steven R. ;

Johnston, Karen C. ;

Buchsbaum, Richard ;

Levy, Gilberto ;

Levin, Bruce .

STROKE, 2010, 41 (04) :707-711

[9] A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke [J].

Haley, EC ;

Lyden, PD ;

Johnston, KC ;

Hemmen, TM .

STROKE, 2005, 36 (03) :607-612

[10] Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial [J].

Hennerici, Michael G. ;

Kay, Richard ;

Bogousslavsky, Julien ;

Lenzi, Gian Luigi ;

Verstraete, Marc ;

Orgogozo, Jean Marc .

LANCET, 2006, 368 (9550) :1871-1878

← 1 2 →